Human Reproduction, Vol 12, 124-131, Copyright © 1997 by Oxford University Press
KG Danielsson, ML Swahn, P Westlund, E Johannisson, M Seppala and M Bygdeman
The effects of low daily doses of the antiprogestin mifepristone (RU 486)
on ovarian and endometrial function were studied. The study included one
control cycle, three treatment cycles and one follow-up cycle. During the
treatment cycles, either 0.1 (n = 5) or 0.5 (n = 5) mg of mifepristone was
administered once daily. Urine samples were collected three times weekly
during the control and treatment cycles and pregnanediol glucuronide and
oestrone glucuronide and luteinizing hormone (LH) were quantified by
radioimmunoassay. Blood samples for cortisol measurement were collected
once weekly and for serum glycodelin at the onset of menstruation. An
endometrial biopsy was obtained in the mid-luteal phase in the control
cycle and in the first and third treatment cycles and analysed by
morphometric and histochemical methods. Binding of Dolichus biflorus
agglutinin (DBA) lectin was measured and expression of progesterone and
oestrogen receptors and glycodelin were analysed immunohistochemically. All
cycles studied were ovulatory with an LH peak and elevated pregnanediol
glucuronide concentrations. Follicular development seemed normal as judged
by ultrasound examination. The length of the menstrual cycle and the
menstrual bleeding were not significantly altered. Following administration
of 0.5 mg mifepristone/day, endometrial development appeared to be slightly
retarded and glandular diameter was significantly reduced. Furthermore,
significant decreases in DBA lectin binding and endometrial expression of
glycodelin were observed. Daily doses of 0.1 mg did not have any
significant effect on the endometrium. No differences in oestrogen or
progesterone receptor immunoactivity between control and treatment cycles
were seen. This study provides further evidence that endometrial function
is sensitive even to doses of antiprogestin that are low enough not to
disturb ovulation. It remains to be established whether these effects are
sufficient to prevent implantation.
ARTICLES
Effect of low daily doses of mifepristone on ovarian function and endometrial development
Department of Woman and Child Health, Karolinska Hospital, Stockholm, Sweden.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  F. M. Horne and D. L. Blithe Progesterone receptor modulators and the endometrium: changes and consequences Hum. Reprod. Update, November 1, 2007; 13(6): 567 - 580. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P.G.L. Lalitkumar, S. Lalitkumar, C.X. Meng, A. Stavreus-Evers, F. Hambiliki, U. Bentin-Ley, and K. Gemzell-Danielsson Mifepristone, but not levonorgestrel, inhibits human blastocyst attachment to an in vitro endometrial three-dimensional cell culture model Hum. Reprod., November 1, 2007; 22(11): 3031 - 3037. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Gemzell-Danielsson and L. Marions Mechanisms of action of mifepristone and levonorgestrel when used for emergency contraception Hum. Reprod. Update, July 1, 2004; 10(4): 341 - 348. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.M. Borman, K.M. Schwinof, C. Niemeyer, K. Chwalisz, R.L. Stouffer, and M.B. Zelinski-Wooten Low-dose antiprogestin treatment prevents pregnancy in rhesus monkeys and is reversible after 1 year of treatment Hum. Reprod., January 1, 2003; 18(1): 69 - 76. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. T Baird Clinical Uses of Antiprogestogens Reproductive Sciences, January 1, 2000; 7(1_suppl): S49 - S52. [Abstract] [PDF]
|
|